MMIT maps the gap between covered and treated

The oncology drug had cleared a hurdle. According to an MMIT case study, its manufacturer had secured favorable placement with most major payers. Adoption was supposed to follow. It didn’t. Somewhere between the insurance company’s list and the clinician’s decision, the logic of the launch had come apart.

This is a useful place to meet MMIT. The company works in the space where a reassuring word, covered, acquires footnotes. It sells the data, software and research that help pharmaceutical teams examine those footnotes and decide what to do next.

01 / A yes with conditions

A formulary is a list of medicines a health plan covers. That sounds binary. MMIT’s business depends on the details inside the answer: which benefit applies, which restrictions accompany coverage, and how the position compares with competing therapies.

For a manufacturer, those distinctions affect where account teams spend their time. For a provider, coverage information can help clarify the administrative route to a therapy. MMIT supplies intelligence to both sides of that conversation. It does not make the insurer’s decision.

Its Mosaic product brings formulary, coverage and medical policy intelligence into an analytics environment. Teams can compare therapies across payers and geographies, inspect restrictions and validate changes against documentation. Ella AI adds a plain-language way to question that data. The proposition is straightforward: less assembly work before a useful answer.

02 / The second set of gatekeepers

Return to the stalled oncology launch. The manufacturer turned to MMIT’s research on integrated delivery networks, or IDNs: health systems with their own formularies and implementation processes. Payer permission had left another layer unexplained.

Account teams used that research to refine outreach. MMIT reports formulary wins at three IDNs. At four others, the drug was already listed, but competing order sets, patient stratification pathways and additional testing requirements interfered with adoption. The reported result was a 17% utilization increase over six months.

That is a company-published, anonymized case, rather than a controlled experiment. Its useful lesson is narrower than a promise of similar results: inspect the local machinery before assuming the coverage headline explains performance.

03 / A database that asks people why

MMIT’s expertise spans clinicians, data specialists and market researchers. That combination matters because a policy tells you what an organization published; research can investigate how decision-makers understand it and put it into practice.

Message Monitor, for example, collects structured feedback after payer conversations. It scores messaging on relevance, credibility and delivery, and lets teams compare their approach with competing messages. The question is refreshingly uncomfortable: did the evidence persuade anyone, or did the meeting merely happen?

Landscape iQ tackles a different ambiguity: who influences access? It maps relationships among payers, pharmacy benefit managers and other organizations, and segments enrollment beyond a single total. Searchlight watches policy changes, offering tailored alerts, summaries and document comparisons. Different tools, different blind spots.

That human layer also shapes the workplace MMIT describes: collaboration across specialties, town halls, volunteer time off and flexibility about working remotely or in person. These are employer statements. The practical point is the mix of disciplines. Interpreting a coverage change and helping a commercial team respond requires clinical context, reliable data and an understanding of the people making decisions.

04 / Selling the distance to a decision

MMIT is an enterprise information business. Clients buy subscriptions and licensed solutions, with research, advisory work and integrations extending the relationship. Public testimonials name Phathom Pharmaceuticals and Neurocrine Biosciences. MMIT describes serving hundreds of manufacturers and life sciences organizations.

The portfolio reaches into execution. FormTrak places coverage messaging within Veeva CRM workflows for field teams. CoverageFinder supports digital coverage lookup. Contract Validation checks whether formulary and medical benefit positions match contractual commitments, helping teams investigate rebate leakage.

The spending question is specific to the buyer: which licensed tools, which data and how much advisory support? A useful evaluation would compare that scope against the staff time spent reconciling policies and the decisions delayed while they do it. That is a purchasing framework, not a calculated return.

05 / A larger family, a specific job

MMIT’s roots lie in Medi-Media. Acquisitions added Atlantic Information Services, Zitter Health Insights and RJ Health, extending its reach across health-plan information, specialty-drug research and reimbursement coding. The pattern is a business collecting adjacent pieces of the access problem.

MMIT and Evaluate joined forces in 2021. In 2022, MMIT became part of Norstella alongside complementary businesses; the group completed its Citeline merger that November. The announced $5 billion figure described the combined Norstella company. It was not MMIT’s standalone valuation.

NorstellaLinQ broadens the available evidence through linked real-world data, including claims, laboratory information and electronic medical records. MMIT’s place in that family remains distinct: understanding coverage and the barriers between a commercial plan and actual use.

06 / Faster answers still need judgment

In a September 2026 interview, MMIT’s product team described the customer frustrations shaping Mosaic: slow tools, manual stitching and answers arriving after the opportunity to act. Customer interviews pushed development toward faster, integrated analysis.

“Nobody wants to spend more money on data to get a slower answer!”Carolyn Zele · MMIT · September 2026

Smart Access takes that ambition into forecasting, using historical therapy analogs to estimate future payer behavior. The assumptions deserve attention: an unusual therapy or changing payer environment can make yesterday’s comparator less useful. Better policy visibility also cannot, by itself, fix affordability or rewrite a hospital workflow.

IQVIA offers overlapping market access intelligence, so buyers have alternatives to examine. MMIT’s case rests on combining coverage detail, human research and tools for action. The reader can copy its underlying question without buying anything: after the official yes, who still has to do what?